Brainsway Ltd ADR (BWAY) Stock Price, Quote & News

Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitatio...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 2 582 4030

Website: www.brainsway.com

Address:

16 Hartum St, Har Hotzvim, Jerusalem, Israel

BrainsWay Dec. 4 at 9:46 AM

$BWAY On December 1, BWAY held a Virtual Analyst and Investor Day to present updates on its growth strategy and the clinical impact of Deep TMS™ for the treatment of mental health and addiction conditions. Key highlights include: - Clinical Insights - Strategic Partnerships - Treatment Overview - Accelerated Protocols - Interactive Q&A Rewatch the event here: https://lifescievents.com/event/hbg2t9aj/

0 · Reply

BrainsWay Dec. 2 at 9:17 AM

$BWAY BrainsWay’s global expansion strategy is supported by large, underserved patient populations and established partnerships across key international markets. Deep TMS™ is positioned to play a transformative role in mental health care far beyond the U.S. International Growth Opportunities Include: • Europe: 37M depression patients • India: 57M depression patients • China: 71M depression patients • Japan: 6M depression patients • Australia: 1.3M depression patients These regions represent some of the largest global markets for depression treatment, offering substantial long-term growth potential. BrainsWay’s expanding network of partners, combined with its proven clinical outcomes and established reimbursement infrastructure, provides a strong platform for accelerated international adoption.

0 · Reply

dup007 Dec. 1 at 9:56 AM

$BWAY I forsee todays interest in the Virtual Analyst & Investor Day drive sp above 52w/h

0 · Reply

BrainsWay Nov. 27 at 9:43 AM

$BWAY With an installed base of more than 1,600 Deep TMS™ systems and over 7 million individual treatments delivered, BrainsWay’s technology has become one of the most widely adopted solutions in the TMS landscape. BrainsWay’s expanding clinical footprint is supported by four FDA-cleared indications: 2013: Major Depressive Disorder (MDD) 2018: Obsessive-Compulsive Disorder (OCD) 2020: Smoking Addiction 2021: Anxious Depression BrainsWay is well-positioned to capitalize on rising clinical demand, expand global penetration, and continue delivering innovation in mental health treatment. The combination of regulatory momentum, a growing installed base, and new treatment protocols creates a strong foundation for future growth and long-term shareholder value.

0 · Reply

BrainsWay Nov. 26 at 1:05 PM

$BWAY We are pleased to share our latest investor presentation, highlighting a strong quarter of growth and an enhanced financial outlook. BrainsWay is clearly executing on its strategy, with robust growth in hardware shipments, strong margin maintenance, and meaningful profitability improvement. The expanding installed base and rising RPO provide high visibility into future revenue streams. With improved full-year guidance, the company is leveraging its momentum and scaling from a solid foundation. We invite you to review the full presentation for additional detail and analysis: https://investors.brainsway.com/static-files/2902f3d8-e9b7-4fb1-9114-4e0c60d993a3

0 · Reply

BEATOFtheMARKET Nov. 21 at 3:29 PM

$BURL $BV $BVN $BWAY $BWIN

0 · Reply

prismmarketview Nov. 20 at 4:16 PM

This Great American Smokeout feature highlights how innovators are transforming smoking cessation and addiction treatment, spotlighting emerging therapies, digital health tools, and biotech companies working to help millions of people quit tobacco and nicotine for good. Among the companies advancing this progress are: MIRA Pharmaceuticals, (NASDAQ: $MIRA) Achieve Life Sciences, (NASDAQ: $ACHV) BrainsWay Ltd. (NASDAQ: $BWAY) https://prismmarketview.com/great-american-smokeout-a-spotlight-on-innovation-in-smoking-cessation-and-addiction-treatment/

0 · Reply

BrainsWay Nov. 20 at 10:08 AM

$BWAY It has been an incredible past week for BrainsWay. We announced three major milestones that together underscore our momentum and position us for sustained growth: Q3 2025 Financial & Operational Results: Revenue rose 29% year-over-year to $13.5 M. Operating income reached $1.3 M, and Adjusted EBITDA rose ~80% to $2.0 M. Installed base exceeded 1,600 systems, and remaining performance obligations totaled ~$65 M. Regulatory Expansion - FDA Clearance: Our Deep TMS™ system received FDA clearance as an adjunct therapy for adolescents (15-21 years) with major depressive disorder (MDD). With this label expansion, Deep TMS becomes the first and only TMS device cleared for patients aged 15-86 for MDD. Clinical Trial Launch - Deep TMS 360™ for Alcohol Use Disorder: We initiated our first clinical trial of the Deep TMS 360™ system targeting alcohol use disorder (AUD) at multiple U.S. and international sites, further extending our development pipeline into addiction-therapeutics.

0 · Reply

BrainsWay Nov. 19 at 10:22 AM

$BWAY “BrainsWay’s new Deep TMS 360 system is an exciting evolution of our platform, designed to deliver more robust stimulation patterns,” said Dr. Colleen Hanlon, Vice President of Medical Affairs, BrainsWay. “We anticipate this study will advance our understanding of how noninvasive neuromodulation can help reduce alcohol cravings and promote long-term recovery.”

0 · Reply

BrainsWay Nov. 18 at 10:07 AM

$BWAY BREAKING: We’re thrilled to share that BrainsWay has just launched its first multicenter clinical trial of the Deep TMS 360™ system for Alcohol Use Disorder (AUD)! This is truly next-generation neuromodulation, and its potential could change lives. Here’s why this matters: - The Deep TMS 360 system delivers more comprehensive and uniform brain stimulation, thanks to its multichannel architecture. - AUD is a huge problem: despite existing therapies, up to 60% of patients relapse within 3–6 months. This trial will enroll 200+ patients (18–86 yrs) with moderate to severe AUD, in a randomized, double-blind, sham-controlled design, across the U.S., Israel, and Sweden. - Treatment regimen is intense: 2 sessions/day for 3–5 weeks, then weekly maintenance for 6 months. Primary endpoint: no heavy drinking days in the first 4 months — a clinically meaningful measure in AUD research. https://finance.yahoo.com/news/brainsway-launches-first-clinical-trial-123000060.html

0 · Reply

BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript

Nov 25, 2025, 7:30 AM EST - 10 days ago

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS™ Treatment December 1, 2025

Nov 17, 2025, 7:30 AM EST - 18 days ago

BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder

Nov 13, 2025, 6:00 AM EST - 22 days ago

BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

Nov 11, 2025, 10:41 AM EST - 23 days ago

BrainsWay Ltd. (BWAY) Q3 2025 Earnings Call Transcript

Nov 11, 2025, 7:30 AM EST - 24 days ago

BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 4, 2025, 8:00 AM EST - 4 weeks ago

BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder

Oct 28, 2025, 8:00 AM EDT - 5 weeks ago

BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025

Oct 27, 2025, 7:30 AM EDT - 5 weeks ago

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers

Aug 21, 2025, 7:30 AM EDT - 3 months ago

BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.

Aug 20, 2025, 7:30 AM EDT - 3 months ago

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

Aug 13, 2025, 3:21 PM EDT - 4 months ago

BrainsWay Ltd. (BWAY) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:30 AM EDT - 4 months ago

BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights

Jun 11, 2025, 7:30 AM EDT - 6 months ago

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)

Jun 10, 2025, 8:00 AM EDT - 6 months ago

BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego

Jun 4, 2025, 7:30 AM EDT - 6 months ago

BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC

May 13, 2025, 10:16 AM EDT - 7 months ago

BrainsWay Ltd. (BWAY) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:30 AM EDT - 7 months ago

BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights

Mar 11, 2025, 10:17 AM EDT - 9 months ago

BrainsWay Ltd. (BWAY) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 9 months ago

BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Dec 12, 2024, 8:00 AM EST - 1 year ago

BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder

Nov 20, 2024, 8:00 AM EST - 1 year ago

BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy

Nov 12, 2024, 12:59 PM EST - 1 year ago

BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:30 AM EST - 1 year ago

BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights

Oct 29, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024

Oct 9, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea

Sep 30, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners

Sep 16, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Announces Significant Expansion on U.S. East Coast

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals

Aug 29, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Appoints Richard A. Bermudes, M.D.

Aug 13, 2024, 4:40 AM EDT - 1 year ago

BrainsWay: Operating Leverage Driving Upside

Aug 6, 2024, 12:03 PM EDT - 1 year ago

BrainsWay Ltd. (BWAY) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights

Jul 23, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 17, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada

Jun 10, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression

Jun 3, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression

May 9, 2024, 9:00 AM EDT - 1 year ago

BrainsWay: Cash Flows Are Underappreciated

May 8, 2024, 1:16 PM EDT - 1 year ago

BrainsWay Ltd. (BWAY) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights

Apr 24, 2024, 8:00 AM EDT - 1 year ago

BrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024

Apr 4, 2024, 8:00 AM EDT - 1 year ago

BrainsWay Announces Published Review Results Highlighting Potential of Deep TMS™ to Treat Parkinson's Disease

Mar 18, 2024, 7:30 AM EDT - 1 year ago

BrainsWay Broadens Partnership with Katie's Way Plus Through Order of an Additional 18 Deep TMS™ Systems

Mar 6, 2024, 10:04 AM EST - 1 year ago

BrainsWay Ltd. (BWAY) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:30 AM EST - 1 year ago

BrainsWay Reports Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights

Feb 21, 2024, 8:00 AM EST - 1 year ago

BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Jan 10, 2024, 7:30 AM EST - 2 years ago

BrainsWay Initiates Clinical Evaluation of Rotational Field “Deep TMS 360°™” Technology

Dec 19, 2023, 7:30 AM EST - 2 years ago

BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network

Dec 7, 2023, 8:00 AM EST - 2 years ago

BrainsWay Announces Continued Expansion of Deep TMS™ in South Korea

Nov 20, 2023, 7:30 AM EST - 2 years ago

Louisiana Insurer Expands Deep TMS™ Access for 1.9 Million Covered Lives

BrainsWay Dec. 4 at 9:46 AM

0 · Reply

BrainsWay Dec. 2 at 9:17 AM

0 · Reply

dup007 Dec. 1 at 9:56 AM

$BWAY I forsee todays interest in the Virtual Analyst & Investor Day drive sp above 52w/h

0 · Reply

BrainsWay Nov. 27 at 9:43 AM

0 · Reply

BrainsWay Nov. 26 at 1:05 PM

0 · Reply

BEATOFtheMARKET Nov. 21 at 3:29 PM

$BURL $BV $BVN $BWAY $BWIN

0 · Reply

prismmarketview Nov. 20 at 4:16 PM

0 · Reply

BrainsWay Nov. 20 at 10:08 AM

0 · Reply

BrainsWay Nov. 19 at 10:22 AM

0 · Reply

BrainsWay Nov. 18 at 10:07 AM

0 · Reply

DARKP00L Nov. 17 at 12:39 PM

$BWAY 07:38 on Nov. 17 2025 BrainsWay Commences Multicenter Clinical Study Evaluating Deep TMS 360 System In Patients With Alcohol Use Disorder #tradeideas

0 · Reply

prismmarketview Nov. 13 at 9:37 PM

(NASDAQ: $BWAY) #BrainsWay's Deep TMS™ system has received FDA clearance for use as an adjunct therapy in adolescents aged 15 to 21 with major depressive disorder. This makes it the first TMS device cleared to treat depression across the widest age range, from 15 to 86 years. The approval is based on real-world data showing meaningful improvement in depression symptoms with a good safety profile. Deep TMS offers a noninvasive treatment option alongside other therapies for adolescents with depression. https://prismmarketview.com/brainsway-gains-fda-clearance-for-deep-tms-as-adjunct-therapy-for-adolescents-with-major-depressive-disorder/

0 · Reply

JarvisFlow Nov. 13 at 6:01 PM

HC Wainwright & Co. has updated their rating for BrainsWay ( $BWAY ) to Buy with a price target of 18.

0 · Reply

OpenOutcrier Nov. 13 at 1:12 PM

$BWAY (+4.5% pre) BrainsWay (NASDAQ: BWAY) wins FDA 510(k) to add Deep TMS adjunct for MDD in ages 15–21 https://ooc.bz/l/84353

0 · Reply

BrainsWay Nov. 13 at 11:19 AM

$BWAY BrainsWay continues to expand its leadership in mental health innovation, exploring new therapeutic indications, faster treatment protocols, and broader market adoption through strategic collaborations such as our recent investment in NeuroLief. Here is what our CEO, Hadar Levy, had to say in the recent Q3 earnings press release. #BrainsWay #BrainsWayLTD #TMS #DeepTMS #BrainHealth

0 · Reply

JarvisFlow Nov. 12 at 6:07 PM

Northland Capital Markets has adjusted their stance on BrainsWay ( $BWAY ), setting the rating to Outperform with a target price of 19 → 23.

0 · Reply

BrainsWay Nov. 12 at 2:41 PM

$BWAY Q3 of 2025 has been a record-breaking quarter for BrainsWay. In yesterday’s announcement, we proudly shared our recent financial and operational highlights. In case you missed it, read our official earnings release here: https://finance.yahoo.com/news/brainsway-reports-third-quarter-2025-123000184.html You can also rewatch our live earnings announcement conference call from yesterday, here: https://viavid.webcasts.com/starthere.jsp?ei=1739288&tp_key=977db37f6c

0 · Reply

FordFG Nov. 11 at 3:47 PM

$BWAY so why is this down 9% after a great earnings report??

0 · Reply

BrainsWay Nov. 11 at 3:13 PM

$BWAY We at BrainsWay are thrilled to announce our record-breaking Q3 2025 Financial Results and Operational Highlights. Revenue has surged 29% to $13.5 million in Q3 2025 compared to Q3 2024, an incredible increase that underscores the growing impact and success of TMS at BrainsWay. Further highlights include: • Operating income reached $1.3 million, and Adjusted EBITDA climbed ~80% to $2.0 million • Remaining performance obligations grew to $65 million, reflecting strong multi-year customer demand • The FDA cleared an accelerated Deep TMS™ protocol for patients with major depressive disorder (MDD) • Raised midpoint of full-year 2025 Revenue and EBITDA guidance Read the full press release here: https://www.globenewswire.com/news-release/2025/11/11/3185329/17676/en/BrainsWay-Reports-Third-Quarter-2025-Financial-Results-and-Operational-Highlights.html

0 · Reply

OpenOutcrier Nov. 11 at 1:24 PM

$BWAY (+3.0% pre) BrainsWay GAAP EPS of $0.04 in-line, revenue of $13.51M beats by $0.47M https://ooc.bz/l/84040

0 · Reply

DARKP00L Nov. 4 at 1:34 PM

$BWAY 08:09 on Nov. 04 2025 BrainsWay Awarded $2.5M Grant From U.S. NIH To Support Clinical Trial Evaluating Deep Transcranial Magnetic Stimulation Protocol Through BrainsWay's Device For Alcohol Use Disorder Treatment #tradeideas

0 · Reply

BrainsWay Oct. 30 at 8:32 AM

$BWAY BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025 Ahead of the call, here’s a look back at Q2 2025 highlights: BrainsWay closed a record-breaking quarter (Q2), reflecting strong demand for our noninvasive neurostimulation tech & commitment to advancing mental health care. Key Highlights: • Revenue: $12.6M, up 26% YoY • EBITDA: +40% YoY in H1 2025 • Net Profit: $2M, up 240% YoY • Performance Obligations: $62M, up 25% YoY • Cash Flow: 8 consecutive quarters of positive free cash flow • Guidance: Raised full-year 2025 Revenue and EBITDA outlook Operational Momentum: • 88 systems shipped in Q2 (+35% YoY); global installed base reached 1,522 systems • ~70% of recent customer engagements structured as multi-year lease agreements Strategic Partnerships: • Completed equity financings with Stella MSO and Axis MSO, two leading clinic networks

0 · Reply

Market Cap	338.41M
Revenue (ttm)	41.02M
Net Income (ttm)	2.92M
EPS (ttm)	N/A
PE Ratio	57.67
Forward PE	51.90
Profit Margin	7.12%
Debt to Equity Ratio	0.00

Volume	34,900
Avg Vol	66,306
Day's Range	N/A - N/A
Shares Out	19.56M
Stochastic %K	84%
Beta	1.22
Analysts	Strong Sell
Price Target	$20.00